N/A
N=89
Functional Interval Training for Veterans Exercising Through Telehealth.
HIV Infection
Bottom Line
View on ClinicalTrials.gov: NCT04103593 ↗Enrolled (actual)
89
Serious AEs
3.4%
Results posted
Jan 2026
Primary outcome: Primary: Change From Baseline VO2peak to After 12-week Exercise Intervention — 1.99; 2.05; 2.07; 2.07 Liters/minute
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- exercise training (Behavioral)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline VO2peak to After 12-week Exercise Intervention |
1.99; 2.05; 2.07; 2.07; 0.09; 0.00 | — |
| SECONDARY Change From Baseline DNA Methylation to After 12-week Exercise Intervention |
— | — |
Summary
Most Veterans living with HIV are 50 years of age or older and can expect to live more than 20 years longer with HIV medication. However, despite this success, Veterans living with HIV are more likely to have age-related diseases and loss of fitness and muscle that place them at increased risk for disability. This is a major priority for the VHA, the largest provider of HIV care in the United States. The goal of this study is to test a circuit exercise program in Veterans living with HIV that is designed to slowdown the aging process. The exercise program will be widely available by Video Teleconferencing (VTEL) and does not require stationary exercise equipment, making it widely accessible. This research will help reach the goal for Veterans to preserve their quality of life and ability to function independently. Novel findings will strengthen strategies to maintain life-long fitness through a personalized exercise prescription.
Eligibility Criteria
Inclusion Criteria
- Veteran living with HIV and under care at VAMC
- 50 years of age and older
- Stable antiretroviral therapy (same ARV medications within 3 months)
- At least one HIV-1 PCR 180 &/or DBP > 110 mm Hg)
- Therapy with beta blockers or non-dihydropyridine calcium channel blocker (within 1 month)
- Screening EKG with ischemia, complex arrhythmia, or high-grade block (per Minnesota Code)
- Poorly controlled DM within prior 1 month (FBS>180 mg/dl, RBS > 299 mg/dl, or HbA1C > 10)
- Receiving treatment for cancer except skin cancer (within 3 months)
- Peripheral vascular disease with claudication
- Severe arthritis limiting ambulation
- Neurologic disease limiting ambulation (requiring assist device)
- End stage liver disease (decompensated liver disease)
- Chronic renal failure (requiring dialysis)
- Severe pulmonary disease (home O2, admission for dyspnea or pneumonia within 1 month)
- Use of systemic steroids (testosterone or glucocorticoids) or growth hormone (within 6 months)
- Dementia (based on Evaluation to Consent)
- Signs or symptoms of any medical comorbidity that would preclude exercise testing or training
- Exercise on routine basis (structured aerobic exercise > 3 times per week) within 1 month
- Past medical history of COPD or emphysema AND mMRC score =4
Data sourced from ClinicalTrials.gov (NCT04103593). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.